Fosnetupitant and palonosetron injection and Metronidazole
Determining the interaction of Fosnetupitant and palonosetron injection and Metronidazole and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this minor interaction is not currently available. Some minor drug interactions may not be clinically relevant in all patients. Minor drug interactions do not usually cause harm or require a change in therapy. However, your healthcare provider can determine if adjustments to your medications are needed.
Professional:Limited data suggest that metronidazole may rarely prolong the QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. There have been isolated reports of QT prolongation and ventricular arrhythmias occurring in patients treated with metronidazole. However, a causal relationship has not been established, as nearly all published reports have involved underlying conditions and/or concomitant medications that predispose to QT prolongation. In general, the risk of an individual agent or a combination of agents causing ventricular arrhythmia in association with QT prolongation is largely unpredictable but may be increased by certain underlying risk factors such as congenital long QT syndrome, cardiac disease, and electrolyte disturbances (e.g., hypokalemia, hypomagnesemia). In addition, the extent of drug-induced QT prolongation is dependent on the particular drug(s) involved and dosage(s) of the drug(s). Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.
- Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F "QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone." Pacing Clin Electrophysiol 28 (2005): 472-3
Generic Name: fosnetupitant / palonosetron
Brand name: Akynzeo for injection
Synonyms: Fosnetupitant and palonosetron (injection), Fosnetupitant and Palonosetron
Generic Name: metronidazole
Brand name: Flagyl, MetroGel, FIRST Metronidazole, Flagyl 375
Synonyms: MetroNIDAZOLE (Systemic)
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Fosnetupitant and palonosetron injection-MetroNIDAZOLE (Systemic)
- Fosnetupitant and palonosetron injection-Metronidazole Capsules
- Fosnetupitant and palonosetron injection-Metronidazole Cream
- Fosnetupitant and palonosetron injection-Metronidazole Cream, Gel, and Lotion
- Fosnetupitant and palonosetron injection-Metronidazole Extended Release
- Fosnetupitant and palonosetron injection-Metronidazole Gel
- Metronidazole-Fosnetupitant/palonosetron Intravenous
- Metronidazole-Fosphenytoin
- Metronidazole-Fosphenytoin Injection
- Metronidazole-Fosphenytoin Sodium
- Metronidazole-Fospropofol Intravenous
- Metronidazole-Fosrenol